|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
AU2002248372B8
(en)
|
2001-01-19 |
2008-03-20 |
Vegenics Limited |
FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
|
ATE500842T1
(de)
|
2002-05-04 |
2011-03-15 |
Acorda Therapeutics Inc |
Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
|
|
ES2278333T3
(es)
*
|
2003-03-28 |
2007-08-01 |
Regeneron Pharmaceuticals, Inc. |
Antagonistas de vegf para el tratamiento de la diabetes.
|
|
MX351062B
(es)
*
|
2003-05-16 |
2017-09-29 |
Acorda Therapeutics Inc |
Proteinas de fusion para el tratamiento del snc.
|
|
EP3211084B1
(en)
|
2003-05-16 |
2019-03-27 |
Acorda Therapeutics, Inc. |
Proteoglycan degrading mutants for treatment of cns
|
|
US7959914B2
(en)
|
2003-05-16 |
2011-06-14 |
Acorda Therapeutics, Inc. |
Methods of reducing extravasation of inflammatory cells
|
|
AU2004242586C1
(en)
*
|
2003-05-28 |
2011-02-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection by using VEGF antagonists
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
CA2519875C
(en)
|
2003-06-06 |
2014-01-14 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with vegf inhibitors
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
*
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
JP2007501239A
(ja)
*
|
2003-08-06 |
2007-01-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
放射線治療と組み合わせたｖｅｇｆアンタゴニストの使用
|
|
EP1750757B1
(en)
|
2004-05-18 |
2013-03-13 |
Acorda Therapeutics, Inc. |
Methods of purifying chondroitinase and stable formulations thereof
|
|
DK1767546T3
(da)
|
2004-06-08 |
2012-04-23 |
Chengdu Kanghong Biotechnologies Co Ltd |
Angiogenese-inhiberende kimært protein og dets anvendelse
|
|
CN101102786A
(zh)
*
|
2004-06-10 |
2008-01-09 |
瑞泽恩制药公司 |
施用并利用vegf抑制剂治疗人类癌症的方法
|
|
US20050281822A1
(en)
*
|
2004-06-18 |
2005-12-22 |
Cedarbaum Jesse M |
Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
|
|
US7378095B2
(en)
|
2004-07-30 |
2008-05-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating type I diabetes by blocking VEGF-mediated activity
|
|
PT2229956E
(pt)
|
2004-09-13 |
2013-07-31 |
Genzyme Corp |
Contruções multiméricas
|
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
|
WO2006088650A2
(en)
*
|
2005-02-02 |
2006-08-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
|
DK2586459T3
(en)
|
2005-03-25 |
2017-09-11 |
Regeneron Pharma |
VEGF antagonist formulations
|
|
CA2623635C
(en)
|
2005-09-26 |
2013-04-02 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase abci mutants
|
|
PL1962895T3
(pl)
†
|
2005-12-16 |
2013-06-28 |
Regeneron Pharma |
Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
RU2432155C3
(ru)
|
2006-06-16 |
2017-11-17 |
Ридженерон Фармасьютикалз, Инк. |
Составы антагониста vegf, подходящие для интравитреального введения
|
|
ME02371B
(me)
|
2006-09-29 |
2016-06-20 |
Oncomed Pharm Inc |
Sastojci i postupci za dijagnstikovanje i tretman raka
|
|
ES2473610T3
(es)
|
2006-10-10 |
2014-07-07 |
Acorda Therapeutics, Inc. |
Composiciones y métodos de uso de mutantes de condroitinasa ABCI
|
|
FR2918279B1
(fr)
*
|
2007-07-05 |
2010-10-22 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
|
|
CN101575379B
(zh)
*
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
WO2010060748A1
(en)
|
2008-11-03 |
2010-06-03 |
Molecular Partners Ag |
Binding proteins inhibiting the vegf-a receptor interaction
|
|
CN101838329A
(zh)
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
US8883145B2
(en)
|
2009-10-16 |
2014-11-11 |
Oncomed Pharmaceuticals, Inc. |
Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
|
|
AR081361A1
(es)
*
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
|
PT2601214T
(pt)
|
2010-08-06 |
2017-12-20 |
Genzyme Corp |
Composições de antagonistas de vegf e utilizações destes
|
|
EP3539991A1
(en)
*
|
2011-01-07 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Method for improving physical properties of antibody
|
|
EP3222285A1
(en)
|
2011-01-13 |
2017-09-27 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist to treat angiogenic eye disorders
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
KR101397088B1
(ko)
|
2011-06-10 |
2014-05-19 |
강원대학교산학협력단 |
암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
JP6138815B2
(ja)
*
|
2011-12-01 |
2017-05-31 |
エーピー バイオサイエンシーズ， インコーポレイテッド |
補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
|
|
CN103304668B
(zh)
*
|
2012-03-12 |
2015-10-28 |
江苏健德生物药业有限公司 |
Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
|
|
HUE046134T2
(hu)
|
2012-05-07 |
2020-02-28 |
Allergan Inc |
Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
|
|
WO2014006113A1
(en)
|
2012-07-03 |
2014-01-09 |
Sanofi |
Method of treating cancer by effective amounts of aflibercept
|
|
TW201438736A
(zh)
|
2012-11-14 |
2014-10-16 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑治療卵巢癌之方法
|
|
CA2901226C
(en)
|
2013-02-18 |
2020-11-17 |
Vegenics Pty Limited |
Vascular endothelial growth factor binding proteins
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
CN104193828B
(zh)
*
|
2013-09-12 |
2017-04-05 |
北京韩美药品有限公司 |
同时阻断her2和vegfr信号通路的重组融合蛋白
|
|
PL3065761T3
(pl)
|
2013-11-05 |
2020-05-18 |
Allergan, Inc. |
Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf
|
|
RU2702748C2
(ru)
|
2014-05-12 |
2019-10-11 |
Формикон Аг |
Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
|
|
WO2016008975A1
(en)
|
2014-07-18 |
2016-01-21 |
Sanofi |
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
|
|
JP2016036322A
(ja)
*
|
2014-08-11 |
2016-03-22 |
日本化薬株式会社 |
血管新生因子と結合するキメラタンパク質
|
|
CN112826934A
(zh)
|
2014-12-11 |
2021-05-25 |
拜耳医药保健有限责任公司 |
具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
|
|
GB201503453D0
(en)
|
2015-03-01 |
2015-04-15 |
Jain Arjun |
Endothelin-1"sponge"
|
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
KR101936049B1
(ko)
|
2015-10-15 |
2019-01-08 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 생산방법
|
|
WO2017065559A1
(ko)
|
2015-10-15 |
2017-04-20 |
(주)알테오젠 |
Igg fc 도메인을 가지는 융합 단백질의 생산방법
|
|
EP3377151A1
(en)
|
2015-11-18 |
2018-09-26 |
Formycon AG |
Pre-filled plastic syringe containing a vegf antagonist
|
|
MX382662B
(es)
|
2015-11-18 |
2025-03-11 |
Sio2 Medical Products Inc |
Envase farmacéutico para formulaciones oftálmicas.
|
|
RU2734958C2
(ru)
|
2015-11-18 |
2020-10-26 |
Формикон Аг |
Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
|
|
CA3005391A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Zhuhai Tairuishang Biopharm Ltd. |
Methods and compositions for binding vegf
|
|
DK3384049T3
(da)
|
2015-12-03 |
2023-10-02 |
Regeneron Pharma |
Fremgangsmåder til associering af genetiske varianter med et klinisk resultat hos patienter, der lider af aldersrelateret makuladegeneration behandlet med anti-VEGF
|
|
EP3407868A1
(en)
|
2016-01-26 |
2018-12-05 |
Formycon AG |
Liquid formulation of a vegf antagonist
|
|
JPWO2018070390A1
(ja)
|
2016-10-12 |
2019-08-22 |
第一三共株式会社 |
抗ｒｏｂｏ４抗体と他剤を含む組成物
|
|
CN116327963A
(zh)
|
2016-11-21 |
2023-06-27 |
济世-伊沃泰克生物制品有限公司 |
一种眼科制剂及其用途
|
|
US20200237997A1
(en)
|
2017-05-24 |
2020-07-30 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
US20200171244A1
(en)
|
2017-05-24 |
2020-06-04 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
ES2887046T3
(es)
|
2017-08-17 |
2021-12-21 |
Just Evotec Biologics Inc |
Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes
|
|
JP7183268B2
(ja)
|
2017-11-20 |
2022-12-05 |
ジャスト－エヴォテック バイオロジックス、インコーポレイテッド |
等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
|
|
EP3717636B1
(en)
|
2017-11-27 |
2023-03-08 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
|
CN111465407A
(zh)
|
2017-11-30 |
2020-07-28 |
瑞泽恩制药公司 |
使用vegf拮抗剂治疗生血管性眼病
|
|
US11460452B2
(en)
*
|
2017-12-13 |
2022-10-04 |
Regeneron Pharmaceuticals, Inc. |
Devices and systems for chromatography column bed support management and related methods
|
|
ES3009668T3
(en)
*
|
2018-01-26 |
2025-03-31 |
Univ California |
Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
|
|
CN112203679A
(zh)
|
2018-03-02 |
2021-01-08 |
科达制药股份有限公司 |
Il-6抗体及其融合构建体和缀合物
|
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
JP7235770B2
(ja)
|
2018-05-10 |
2023-03-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
|
US20220204920A1
(en)
|
2019-05-16 |
2022-06-30 |
Formycon Ag |
Method for reducing methionine oxidation in recombinant proteins
|
|
JP2022546082A
(ja)
|
2019-09-03 |
2022-11-02 |
アムジエン・インコーポレーテツド |
薬物送達のための注入デバイス及び注入デバイスのためのパッケージ
|
|
US12233177B2
(en)
|
2019-09-16 |
2025-02-25 |
Amgen Inc. |
Method for external sterilization of drug delivery device
|
|
WO2021072265A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CA3168512A1
(en)
|
2019-11-25 |
2021-06-03 |
Napoleone Ferrara |
Long-acting vegf inhibitors for intraocular neovascularization
|
|
KR20220110555A
(ko)
|
2019-12-06 |
2022-08-08 |
리제너론 파마슈티칼스 인코포레이티드 |
Vegf 미니-트랩 및 그의 사용 방법
|
|
SG11202110968VA
(en)
|
2019-12-06 |
2021-10-28 |
Regeneron Pharma |
Anti-vegf protein compositions and methods for producing the same
|
|
AU2021226754A1
(en)
|
2020-02-24 |
2022-07-07 |
Amgen Inc. |
Containers and systems for use during external sterilization of drug delivery devices
|
|
CA3182893A1
(en)
|
2020-05-08 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Vegf traps and mini-traps and methods for treating ocular disorders and cancer
|
|
EP4329734A4
(en)
|
2021-04-26 |
2025-04-02 |
Celanese EVA Performance Polymers LLC |
Implantable device for the delayed release of a macromolecular drug compound
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
WO2023092324A1
(zh)
|
2021-11-24 |
2023-06-01 |
苏州光度生物科技有限公司 |
多特异性配体结合分子及其应用
|
|
WO2024029876A1
(ko)
*
|
2022-08-02 |
2024-02-08 |
주식회사 파노로스바이오사이언스 |
변형된 융합 단백질 및 이의 용도
|
|
EP4588469A1
(en)
|
2022-09-16 |
2025-07-23 |
Qilu Pharmaceutical Co., Ltd. |
Stable high-concentration self-buffering pharmaceutical composition
|
|
WO2025033876A1
(ko)
*
|
2023-08-04 |
2025-02-13 |
주식회사 파노로스바이오사이언스 |
변형된 융합 단백질과 scFv의 결합체 및 이의 용도
|
|
WO2025213011A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Method of assessing stopper movement in a drug delivery device
|